*To the Editor*:

Stout and colleagues have developed an interesting and potentially useful mathematical model addressing some important issues in noninferiority trials of tuberculosis (TB)-preventive therapy ([@bib1]). They rightly point out that enrolling individuals with no risk of experiencing an endpoint in such trials may result in a greater likelihood of finding noninferiority. Some of the assumptions used in their model, however, are not appropriate for trials of TB-preventive therapy in people with HIV infection.

Stout and colleagues ([@bib1]) used participant parameters from the BRIEF TB (Brief Rifapentine Isoniazid Efficacy for Tuberculosis) study, a large, phase-three randomized trial comparing 1 month of isoniazid and rifapentine (1HP) to 9 months of isoniazid in people with HIV infection ([@bib2]) to assert that a trial in such a population would have an "unacceptably high" probability of declaring noninferiority even if the experimental regimen was in fact inferior to the control regimen. Their explanation for this contention is that a significant proportion of participants in the BRIEF TB study had negative or missing tests for latent TB infection and were, therefore, not at risk of developing TB.

The assumption that people with HIV infection and negative results of a tuberculin skin test (TST) or IFN-γ release assay (IGRA) are not at risk for TB and will not benefit from preventive therapy is incorrect. People with HIV infection are at greatly increased risk of developing TB, particularly in high-burden settings, and preventive therapy has been proved efficacious in the absence of a positive TST or IGRA ([@bib3], [@bib4]). In the trial of Rangaka and coworkers ([@bib3]), individuals with advanced HIV infection and negative TSTs or IGRAs who received a placebo experienced significantly higher rates of TB than those who received isoniazid. Of participants in the Temprano study tested by IGRA, only about one-third had positive results, yet those with negative tests who received isoniazid preventive therapy experienced similar reduction in the incidence of TB and death as those who were IGRA-positive ([@bib4]).

In both arms of the BRIEF-TB trial, individuals with a negative TST or IGRA had rates of TB or death from an unknown cause that were substantially higher than those seen in TST-positive individuals without HIV infection enrolled in the PREVENT TB (Tuberculosis Trials Consortium Study 26) trial, demonstrating their increased risk ([@bib5]). Additionally, the subgroup analysis of individuals in BRIEF-TB who had positive TSTs or IGRAs demonstrated noninferiority of 1HP to isoniazid, with an upper bound of the 95% confidence interval for the difference in rates being 0.73 per 100 person-years, which not only meets the noninferiority margin set for this trial (1.25 per 100 person-years) but also the noninferiority margin used in the PREVENT TB trial and the ongoing ASTERoiD (Assessment of Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI) trial (0.75 per 100 person-years) ([@bib5], [@bib6]).

TB-preventive treatment is essential for achieving global TB control. Although tests of latent TB infection are useful in nonimmunosuppressed patients, it is clear that some populations, such as people with HIV infection and young child household contacts, do not require testing before initiating preventive treatment, a recommendation now endorsed by the World Health Organization ([@bib7]). Studies of TB-preventive therapy in people with HIV infection must enroll the population that will receive the therapy in real-world clinical practice. The BRIEF TB trial demonstrated noninferiority of 1HP to isoniazid in both the overall population and the subset of those with a positive TST or IGRA, making the results generalizable to all HIV-infected adults and adolescents living in high-burden areas, as well as those with a positive test of latent infection anywhere. Requiring a positive TST or IGRA for enrollment into clinical trials of HIV-infected people seems to us like a step in the wrong direction.
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